Later-Line Choices for Patients With Metastatic TNBC

During a live virtual event, Joyce O'Shaughnessy, MD, discussed treatment options for a patient with metastatic triple-negative breast cancer whose disease recurred 8 months after receiving adjuvant therapy.

During a live virtual event, Joyce O'Shaughnessy, MD, discussed participants' experiences with the tolerability of sacituzumab govitecan in patients with metastatic triple-negative breast cancer. The participants also discussed their approaches to molecular testing for biomarkers at the time of disease relapse or progression.

During a live virtual event, Sara Tolaney, MD, discussed the results of the ASCENT trial of sacituzumab govitecan in patients with triple-negative breast cancer.

During a live virtual event, Sara Tolaney, MD, MPH, discussed the common issue of neutropenia in patients with triple-negative breast cancer who received sacituzumab govitecan in the ASCENT trial and in her clinical practice.

Participants of a live, virtual case-based event discussed different scenarios for treatment of a patient with BRCA and PD-L1 negative, metastatic triple-negative breast cancer. Vote in the polls on what you would have chosen if this was your patient.

During a live virtual event, Rita Nanda, MD, discussed the choice of therapy for a patient whose metastatic triple-negative breast cancer recurred after adjuvant chemotherapy with paclitaxel.

During a live virtual event, Rita Nanda, MD, discussed with participants how to address toxicities of sacituzumab govitecan and how to treat a patient who progresses after receiving this agent.

During a Targeted Oncology case-based roundtable event, Elizabeth Ann Mittendorf, MD, discussed with participants their choice of treatment after progression for a patient with triple-negative breast cancer treated with adjuvant dose-dense doxorubicin plus cyclophosphamide with paclitaxel. This is the first of 2 articles based on this event.

During a live virtual event, Elizabeth Ann Mittendorf, MD, PhD, discussed the case of a patient with triple-negative breast cancer whose disease progressed following adjuvant dose-dense doxorubicin plus cyclophosphamide with paclitaxel, then frontline gemcitabine and carboplatin. This is the second of 2 articles based on this live event.

During a Targeted Oncology™ Case-Based Roundtable™ event, Hope S. Rugo, MD, discussed with participants the management of neutropenia and other toxicities associated with the antibody-drug conjugate sacituzumab govitecan in patients with metastatic triple-negative breast cancer.

During a Targeted Oncology™ Case-Based Roundtable™ event, Hope S. Rugo, MD, discussed adverse event management in patients treated with sacituzumab govitecan for triple-negative breast cancer and other therapy options. This is the second of 2 articles based on this event.